RATIONALE: Clinical and epidemiologic approaches have identified two distinct sets of classifications for asthma and wheeze phenotypes. OBJECTIVES: To compare epidemiologic phenotype definitions identified by latent class analysis (LCA) with clinical phenotypes based on patient histories, diagnostic work-up, and treatment responses. To relate phenotypes to genetic and environmental determinants as well as diagnostic and treatment-related parameters. METHODS: LCA was performed in an international multicenter birth cohort based on yearly questions about current wheeze until age 6 years. Associations of wheeze classes and clinical phenotypes with asthma-related characteristics such as atopy, lung function, fraction of exhaled nitric oxide, and medication use were calculated using regression models. MEASUREMENTS AND MAIN RESULTS: LCA identified five classes, which verified the clinically defined wheeze phenotypes with high sensitivity and specificity; the respective receiver operating characteristics curves displayed an area under the curve ranging from 84% (frequent wheeze) to 85% (asthma diagnosis) and 87% (unremitting wheeze) to 97% (recurrent unremitting wheeze). Recurrent unremitting wheeze was the most specific and unremitting wheeze at least once the most sensitive definition. The latter identified a subgroup of children with decreased lung function, increased genetic risk, and in utero smoke exposure (ODDS RATIO, 2.03; 95% CONFIDENCE INTERVAL, 1.12-3.68; P = 0.0191), but without established asthma diagnosis and treatment. CONCLUSIONS: Clinical phenotypes were well supported by LCA analysis. The hypothesis-free LCA phenotypes were a useful reference for comparing clinical phenotypes. Thereby, we identified children with clinically conspicuous but undiagnosed disease. Because of their high area under the curve values, clinical phenotypes such as (recurrent) unremitting wheeze emerged as promising alternative asthma definitions for epidemiologic studies.
RATIONALE: Clinical and epidemiologic approaches have identified two distinct sets of classifications for asthma and wheeze phenotypes. OBJECTIVES: To compare epidemiologic phenotype definitions identified by latent class analysis (LCA) with clinical phenotypes based on patient histories, diagnostic work-up, and treatment responses. To relate phenotypes to genetic and environmental determinants as well as diagnostic and treatment-related parameters. METHODS: LCA was performed in an international multicenter birth cohort based on yearly questions about current wheeze until age 6 years. Associations of wheeze classes and clinical phenotypes with asthma-related characteristics such as atopy, lung function, fraction of exhaled nitric oxide, and medication use were calculated using regression models. MEASUREMENTS AND MAIN RESULTS: LCA identified five classes, which verified the clinically defined wheeze phenotypes with high sensitivity and specificity; the respective receiver operating characteristics curves displayed an area under the curve ranging from 84% (frequent wheeze) to 85% (asthma diagnosis) and 87% (unremitting wheeze) to 97% (recurrent unremitting wheeze). Recurrent unremitting wheeze was the most specific and unremitting wheeze at least once the most sensitive definition. The latter identified a subgroup of children with decreased lung function, increased genetic risk, and in utero smoke exposure (ODDS RATIO, 2.03; 95% CONFIDENCE INTERVAL, 1.12-3.68; P = 0.0191), but without established asthma diagnosis and treatment. CONCLUSIONS: Clinical phenotypes were well supported by LCA analysis. The hypothesis-free LCA phenotypes were a useful reference for comparing clinical phenotypes. Thereby, we identified children with clinically conspicuous but undiagnosed disease. Because of their high area under the curve values, clinical phenotypes such as (recurrent) unremitting wheeze emerged as promising alternative asthma definitions for epidemiologic studies.
Authors: Niloufar Farzan; Susanne J Vijverberg; Anand K Andiappan; Lambang Arianto; Vojko Berce; Natalia Blanca-López; Hans Bisgaard; Klaus Bønnelykke; Esteban G Burchard; Paloma Campo; Glorisa Canino; Bruce Carleton; Juan C Celedón; Fook Tim Chew; Wen Chin Chiang; Michelle M Cloutier; Denis Daley; Herman T Den Dekker; F Nicole Dijk; Liesbeth Duijts; Carlos Flores; Erick Forno; Daniel B Hawcutt; Natalia Hernandez-Pacheco; Johan C de Jongste; Michael Kabesch; Gerard H Koppelman; Vangelis G Manolopoulos; Erik Melén; Somnath Mukhopadhyay; Sara Nilsson; Colin N Palmer; Maria Pino-Yanes; Munir Pirmohamed; Uros Potočnik; Jan A Raaijmakers; Katja Repnik; Maximilian Schieck; Yang Yie Sio; Rosalind L Smyth; Csaba Szalai; Kelan G Tantisira; Steve Turner; Marc P van der Schee; Katia M Verhamme; Anke H Maitland-van der Zee Journal: Pharmacogenomics Date: 2017-06-22 Impact factor: 2.533
Authors: Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay Journal: Lancet Respir Med Date: 2014-05-19 Impact factor: 30.700
Authors: Carolyn S Calfee; David R Janz; Gordon R Bernard; Addison K May; Kirsten N Kangelaris; Michael A Matthay; Lorraine B Ware Journal: Chest Date: 2015-06 Impact factor: 9.410
Authors: Anne M Fitzpatrick; Leonard B Bacharier; Theresa W Guilbert; Daniel J Jackson; Stanley J Szefler; Avraham Beigelman; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Wayne Morgan; Wanda Phipatanakul; Jacqueline A Pongracic; Robert S Zeiger; David T Mauger Journal: J Allergy Clin Immunol Pract Date: 2018-09-26
Authors: Caroline Roduit; Remo Frei; Martin Depner; Anne M Karvonen; Harald Renz; Charlotte Braun-Fahrländer; Elisabeth Schmausser-Hechfellner; Juha Pekkanen; Josef Riedler; Jean-Charles Dalphin; Erika von Mutius; Roger Pascal Lauener; Anne Hyvärinen; Pirkka Kirjavainen; Sami Remes; Marjut Roponen; Marie-Laure Dalphin; Vincent Kaulek; Markus Ege; Jon Genuneit; Sabina Illi; Micahel Kabesch; Bianca Schaub; Petra Ina Pfefferle; Gert Doekes Journal: JAMA Pediatr Date: 2017-07-01 Impact factor: 16.193
Authors: Martin Depner; Diana Hazard Taft; Pirkka V Kirjavainen; Karen M Kalanetra; Anne M Karvonen; Stefanie Peschel; Elisabeth Schmausser-Hechfellner; Caroline Roduit; Remo Frei; Roger Lauener; Amandine Divaret-Chauveau; Jean-Charles Dalphin; Josef Riedler; Marjut Roponen; Michael Kabesch; Harald Renz; Juha Pekkanen; Freda M Farquharson; Petra Louis; David A Mills; Erika von Mutius; Markus J Ege Journal: Nat Med Date: 2020-11-02 Impact factor: 53.440
Authors: Anne M Fitzpatrick; Daniel J Jackson; David T Mauger; Susan J Boehmer; Wanda Phipatanakul; William J Sheehan; James N Moy; Ian M Paul; Leonard B Bacharier; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Jacqueline A Pongracic; Avraham Beigelman; Sachin N Baxi; Mindy Benson; Kathryn Blake; James F Chmiel; Cori L Daines; Michael O Daines; Jonathan M Gaffin; Deborah Ann Gentile; W Adam Gower; Elliot Israel; Harsha Vardhan Kumar; Jason E Lang; Stephen C Lazarus; John J Lima; Ngoc Ly; Jyothi Marbin; Wayne Morgan; Ross E Myers; J Tod Olin; Stephen P Peters; Hengameh H Raissy; Rachel G Robison; Kristie Ross; Christine A Sorkness; Shannon M Thyne; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2016-10-21 Impact factor: 10.793
Authors: Edward Zoratti; Suzanne Havstad; Ganesa Wegienka; Charlotte Nicholas; Kevin R Bobbitt; Kimberley J Woodcroft; Dennis R Ownby; Christine Cole Johnson Journal: Ann Allergy Asthma Immunol Date: 2014-05-05 Impact factor: 6.347